Sun Pharma Reveals New Clinical Data on Severe Dermatological Conditions at 2024 EADV Congress

Sun Pharmaceutical Industries Limited has announced the presentation of several abstracts at the 33rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam from September 25-28, 2024. These presentations will feature clinical efficacy and safety data for LEQSELVI™ (deuruxolitinib) 8 mg tablets, an FDA-approved oral inhibitor of Janus Kinases JAK1 and JAK2, for treating severe alopecia areata (AA) in adults.

Key findings to be presented include a podium presentation showing that over 95% of patients taking deuruxolitinib 8 mg twice daily reported improved hair satisfaction over a 24-week period. This improvement is significant as AA patients often suffer from anxiety and depression due to the disease's visible effects. Additional poster presentations will reveal that patients experienced clinically meaningful improvements in depression and anxiety, as well as optimized dosing results favoring the 8 mg twice-daily regimen over higher once-daily doses.

Dr. Arash Mostaghimi, Vice Chair of Clinical Trials and Innovation at Brigham and Women's Hospital, noted the significance of these findings, emphasizing the dual benefit of addressing both the physical and psychological impacts of hair loss.

The data on LEQSELVI will be complemented by 12 poster presentations highlighting the clinical efficacy and safety of ILUMYA® (tildrakizumab) in treating moderate-to-severe plaque psoriasis. These studies include interim data analyses from real-world settings, showcasing the drug's effectiveness and safety profile.

The abstracts to be presented at the EADV Congress include:

**Deuruxolitinib:**
1. **Podium Presentation [FC04.04]:** Change in patient-reported hair satisfaction during treatment of severe alopecia areata.
2. **Poster Presentation [P2022]:** Improvement in anxiety and depression in adult patients with severe alopecia areata.
3. **Poster Presentation [P2081]:** Optimization of dosing for deuruxolitinib in alopecia areata patients.

**Tildrakizumab:**
1. **Poster Presentation [P3221]:** Comparative efficacy and safety for moderate-to-severe plaque psoriasis.
2. **Poster Presentation [P3177]:** Efficacy and safety through Week 28 in patients with early vs. late-onset moderate-to-severe plaque psoriasis.
3. **Poster Presentation [P3274]:** Improving patient well-being in moderate-to-severe plaque psoriasis.
4. **Poster Presentation [P3348]:** Effectiveness and nail assessment in psoriasis and psoriatic arthritis.
5. **Poster Presentation [P3343]:** Effectiveness in special areas of moderate-to-severe psoriasis.
6. **Poster Presentation [P3341]:** High effectiveness in bio-naïve and bio-experienced patients.
7. **Poster Presentation [P3340]:** High effectiveness regardless of baseline characteristics.
8. **Poster Presentation [P3188]:** Patient-reported well-being in a real-world setting.
9. **Poster Presentation [P3339]:** Safety data from a 52-week study.
10. **Poster Presentation [P3346]:** Effectiveness for itch, pain, and fatigue.
11. **Poster Presentation [P3347]:** Quality of life and work productivity.
12. **Poster Presentation [P3344]:** Impact on partner well-being in a real-world setting.

LEQSELVI™ is designed to target the immune mechanisms underlying alopecia areata, an autoimmune disorder causing hair loss. It is approved for adults with severe AA, a condition associated with significant psychological impacts such as anxiety and depression. The THRIVE-AA1 and THRIVE-AA2 trials, involving over 1,200 patients, demonstrated LEQSELVI's efficacy in regrowing scalp hair over a 24-week period using the Severity of Alopecia Tool (SALT) score.

ILUMYA® (tildrakizumab) is indicated for treating moderate-to-severe plaque psoriasis in adults suitable for systemic therapy or phototherapy. It has shown consistent effectiveness and safety in various clinical studies, with ongoing research supporting its benefits in real-world settings.

Both LEQSELVI™ and ILUMYA® represent significant advancements in dermatological treatments, offering new hope for patients with severe skin conditions. The upcoming presentations at the EADV Congress underscore Sun Pharma's commitment to advancing dermatological care through innovative therapies.